Phase 1 Trial for ASP388B

ASP388B is an experimental anticancer drug now being tested in a first-in-human study for people with advanced solid tumors, including mCRPC. The public trial record shows it is being studied both alone and in combination with standard treatments, but its exact molecular target has not been publicly disclosed in the materials I could verify.

In the first part of the trial, investigators are focused on dose finding and safety; in the second part, they expand into selected tumor groups to look for signs of antitumor effect.

Participants receive the drug in 21-day cycles, either as a single agent or alongside standard cancer therapies. The combination arms include widely used treatments such as pembrolizumab, carboplatin, oxaliplatin, and 5-fluorouracil, suggesting the program is exploring whether the investigational agent can deepen responses when paired with established regimens.

Because this is a first-in-human study, the main early concern is tolerability. The protocol tracks dose-limiting toxicities, adverse events, lab abnormalities, ECG changes, and other standard safety measures to define a usable dose range.

The biggest unanswered question is mechanism. Public documents describe the study’s structure and populations, but they do not clearly state what the drug binds to, how it kills tumor cells, or whether it works through direct cytotoxicity, immune modulation, or another pathway. For now, that leaves it as a mechanistically opaque investigational oncology agent in the public record.

Clinical trial.